Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transactions are expected to generate approximately $4 million in aggregate gross proceeds, subject to customary closing conditions, with closing anticipated on or about October 15, 2026.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs. These securities were offered at a combined purchase price of $1.20 per ADS and accompanying warrant. In addition, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and will receive new warrants to purchase up to 1,318,791 ADSs. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have a five-year term. A.G.P./Alliance Global Partners is serving as sole placement agent for the transactions.
This capital raise is significant because it provides Scinai with additional financial resources to pursue its dual strategic objectives: expanding its CDMO platform and continuing selective investment in its immunotherapy pipeline. The CDMO, Scinai Biopharma Services Ltd., offers development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. By strengthening this service arm, Scinai aims to capture growing demand for outsourced biopharmaceutical development and manufacturing, while also advancing proprietary immunology therapies licensed from the Max Planck Society and PinCell S.r.l.
The involvement of an existing institutional investor, along with the warrant inducement, signals continued confidence in Scinai’s business model. The immediate exercise of existing warrants at a reduced price generates upfront cash and simplifies the company’s capital structure. The new warrants, if exercised in the future, could provide additional capital without the need for further dilutive offerings at lower prices. Management intends to use the net proceeds, together with existing cash resources, to expand the CDMO platform, advance customer programs, and support the immunotherapy pipeline.
For investors and industry observers, this transaction underscores the growing importance of CDMOs in the biopharmaceutical ecosystem. As smaller biotechnology companies seek to reduce fixed costs and accelerate timelines, partnering with established CDMOs like Scinai can be a cost-effective route to clinical and commercial supply. Scinai’s ability to secure funding in a challenging market environment may also serve as a positive indicator for other companies seeking capital for similar dual-track strategies.
The full details of the private placement and warrant inducement are available in the company’s press release, which can be accessed at https://ibn.fm/eUtYO. For ongoing updates on Scinai Immunotherapeutics, the company maintains a newsroom at https://ibn.fm/SCNI. Additional information about the company and its relationship with MissionIR can be found at Scinai Immunotherapeutics (NASDAQ: SCNI).
MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform delivers wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit MissionIR and review the full terms of use and disclaimers at https://www.MissionIR.com/Disclaimer.
